ORIC Pharmaceuticals (ORIC) surges as intriguing ESMO Asia data for Enozertinib prompts Wells Fargo to assign higher value
I'm PortAI, I can summarize articles.
Wells Fargo raised ORIC Pharmaceuticals' price target to $25 from $19 and maintained an Overweight rating, driven by promising ESMO Asia data for Enozertinib.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments